Table 3. Studies describing mortality rate associated with resistant and MDR ESKAPE bacteria.
| Authors | Hospital Wards | Bacteria | Mortality rate | P-value | References |
|---|---|---|---|---|---|
| Al Jarousha et al. (2009) | Neonatal ICU | MDR-A. baumannii (15/40) | 37.5% | 0.001 | [54] |
| Susceptible A. baumannii (12/100) | 12% | ||||
| Anunnatsiri et al. (2011) |
ICU | MDR-A. baumannii (22/24) | 91.7% | 0.001 | [41] |
| Susceptible A. baumannii (12/25) | 48% | ||||
| Amer et al. (2015) | Emergency ICU /Pediatric ICU |
CR-MBLP-P. aeruginosa (14/32) | 43,8% | 0.2 | [64] |
| CR-MBLN-P. aeruginosa (2/8) | 25% | ||||
| Furtado et al. (2009) | ICU | Imipenem-resistant P. aeruginosa (31/63) | 49% | 0.02 | [31] |
| Imipenem-susceptible P. aeruginosa (61/182) | 33% | ||||
| Marra et al. (2006) | ICU | ESBL-producing K. pneumoniae (18/56) | 32.14% | 0.042 | [46] |
| Non-ESBL K. pneumoniae (8/52) | 15.38% | ||||
| Moreira et al. (2008) | ICU | ORSA (11/29) | 37.9% | 0.41 | [47] |
| OSSA (8/32) | 25% | ||||
| Serefhanoglu et al. (2009) | ICU | MDR-ESBL-producing-E. coli and K. pneumoniae (7/30) | 23.3% | 0.606 | [32] |
| Non-MDR-ESBL-producing-E. coli and K. pneumoniae (12/64) | 18.8% | ||||
| Tuon et al. (2012) | ICU | Carbapenem-resistant P. aeruginosa (13/29) | 54.2% | 0.043 | [22] |
| Carbapenem-susceptible P. aeruginosa (26/48) | 44.8% | ||||
| Chen et al. (2012) | ICU | MRSA (25/75) | 33% | 0.01 | [48] |
| MSSA (8/43) | 18.6% | ||||
| Fu et al. (2015) | ICU | XDR A. baumannii (31/39) | 79.5% | 0.1 | [49] |
| Non-XDR A. baumannii (38/86) | 44.2% | ||||
| Jia et al. (2015) | ICU | Linezolid non-susceptible Enterococci (3/44) | 6.8% | 0.521 | [50] |
| Linezolid-susceptible Enterococci (2/44) | 4.5% | ||||
| Un-infected Control patients (3/176) | 1.7% | ||||
| Yao et al. (2015) | ICU | MRSA (12/57) | 21% | 0.002 | [35] |
| MSSA (9/116) | 8% | ||||
| Gomez Rueda et al. (2014) | ICU | Carbapenem resistant K. pneumoniae (31/61) | 50.8% | 0.042 | [36] |
| Carbapenem-susceptible K. pneumoniae (20/61) | 32.7% | ||||
| Un-infected control patients (25/122) | 20.4% | ||||
| Kumar et al. (2014) | ICU | Carbapenem-resistant A. baumannii (9/33) | 27.3% | 0.074 | [37] |
| Carbapenem-susceptible A. baumannii (3/32) | 9.4% | ||||
| Nazer et al. (2015) | ICU | MDR-A. baumannii (118/161) | 73.3% | 0.015 | [53] |
| Non-MDR-A. baumannii (142/232) | 61.2% | ||||
| Deris et al. (2011) | ICU | Imipenem-resistant -A. baumannii (6/15) | 42.9% | 0.201 | [39] |
| Imipenem-susceptible A. baumannii (9/41) | 24.3% | ||||
| Inchai et al. (2015) | ICU | MDR-A. baumannii (10/72) | 13.9% | 0.001 | [44] |
| XDR- A. baumannii (88/220) | 40% | ||||
| PDR-A. baumannii (7/12) | 58.3% | ||||
| Jamulitrat et al. (2009) | ICU | Imipenem-resistant-A. baumannii (35/67) | 52.2% | 0.001 | [59] |
| Imipenem-susceptible A. baumannii (26/131) | 19.9%% | ||||
| Thatrimontrichai et al. (2016) | ICU | Carbapenem-resistant A. baumannii (10/63) | 15.9% | 0.01 | [19] |
| Carbapenem-susceptible A. baumannii (1/13) | 7.7% | ||||
| Un-infected control patients (0/25) | 0% | ||||
| Topeli et al. (2000) | ICU | MRSA (15/46) | 32.6% | 0.02 | [21] |
| MSSA (7/55) | 12.7% |
CR: Carbapenem-resistant; CS: Carbapenem susceptible; MBL: Metallo-beta-lactamase; IS: imipenem sensitive; IR: imipenem resistant; ICU: Intensive Care Unit; OSSA: Oxacillin-sensitive-S. aureus; ORSA: Oxacillin-resistant-S. aureus; PDR: Pan drug resistant; XDR: Extensive drug resistant